Loading
A phase 3 trial testing Bleximenib in acute myeloid leukaemia, now recruiting.
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukaemia (AML) is a phase 3 interventional study registered as NCT06852222, led by Janssen Research & Development, and recruiting on the registry. Official title: A Phase 3 Randomised, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukaemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy. Planned enrolment is 600 participants (estimated). The study started in 2025-06-04 and primary completion is expected in 2029-06-22. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Acute myeloid leukaemia in older or unfit patients.
Shares NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/